CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Rhea-AI Summary

CRISPR Therapeutics announces an oral presentation at the ASGCT 2024 Annual Meeting on the Development of an In Vivo Non-Viral Ocular Editing Platform for Glaucoma treatment.

ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Title: Development of an In Vivo Non-Viral Ocular Editing Platform and Application to Potential Treatments for Glaucoma
Session Type: In-Person Oral Presentation
Session Title: Ophthalmic and Auditory: Delivery Innovations
Abstract Number: 87
Location: Room 318 – 323
Session Date and Time: Wednesday, May 8, 2024, 1:30 p.m. – 3:15 p.m. ET

Abstracts will be released to the public on April 22, 2024, at 4:30 p.m. ET at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 8, 2024. A copy of the presentation will be available at www.crisprtx.com once the presentation concludes.

About CRISPR Therapeutics 
Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company with a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular and rare diseases. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit www.crisprtx.com.  

Investor Contact: 
Susan Kim 
+1-617-307-7503 
susan.kim@crisprtx.com  

Media Contact: 
Rachel Eides 
 +1-617-315-4493 
rachel.eides@crisprtx.com

 

What is the focus of CRISPR Therapeutics' presentation at the ASGCT 2024 Annual Meeting?

CRISPR Therapeutics will present on the Development of an In Vivo Non-Viral Ocular Editing Platform for potential treatments for Glaucoma.

When and where will the presentation take place?

The presentation will be on Wednesday, May 8, 2024, from 1:30 p.m. to 3:15 p.m. ET in Baltimore, MD, and virtually.

When will the abstracts be released to the public?

The abstracts will be released on April 22, 2024, at 4:30 p.m. ET on the ASGCT website.

Where can the presentation be accessed after its conclusion?

A copy of the presentation will be available on www.crisprtx.com after the presentation concludes.